Related Experiment Video
Updated: Oct 30, 2025
10:18
Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
Published on: June 29, 2014
17.3K
QiShenYiQi Pill Improves Myocardial Hypertrophy Caused by Pressure Overload in Rats
Shichao Lv1,2, Qiang Wang1, Meifang Wu1
1The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
Summary
QiShenYiQi pill (QSYQ) effectively treats pressure-overloaded myocardial hypertrophy in rats. This cardiovascular disease treatment works by regulating TGF-β1 and CTGF pathways, offering new insights into QSYQ
Area of Science:
- Cardiovascular Research
- Pharmacology
- Integrative Medicine
Background:
- Pressure-overloaded myocardial hypertrophy is a significant risk factor for cardiovascular diseases (CVDs), including heart failure and arrhythmia.
- QiShenYiQi pill (QSYQ) is a traditional Chinese medicine used for CVDs, but its mechanism in treating myocardial hypertrophy remains unclear.
Purpose of the Study:
- To investigate the therapeutic effect and underlying mechanism of QSYQ on pressure-overloaded myocardial hypertrophy in a rat model.
- To explore the role of TGF-β1 and CTGF in QSYQ's cardioprotective effects.
Main Methods:
- A rat model of myocardial hypertrophy was induced by abdominal aortic constriction.
- Rats were treated with QSYQ, valsartan (positive control), or vehicle.
- Cardiac morphology, collagen content, and expression of key molecular markers (ANP, β-MHC, TGF-β1, CTGF) were assessed at 4 and 8 weeks.
Main Results:
- QSYQ treatment significantly improved cardiac morphology and reduced myocardial hypertrophy in pressure-overloaded rats.
- QSYQ administration modulated the expression of collagen types I and III and reduced collagen volume fraction.
- The expression levels of TGF-β1 and CTGF were significantly altered by QSYQ treatment, suggesting their involvement in the therapeutic effect.
Conclusions:
- QSYQ demonstrates significant efficacy in ameliorating pressure-overloaded myocardial hypertrophy in rats.
- The cardioprotective mechanism of QSYQ is associated with the regulation of TGF-β1 and CTGF signaling pathways.
- These findings support the potential of QSYQ as a therapeutic agent for cardiovascular diseases involving myocardial hypertrophy.
More Related Videos
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
104
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
104
01:29Cardiomyopathy V: Interprofessional Care
78
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
78
01:14Myocarditis III: Medical Management
41
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
41